Mikrogen‘s scope of business covers the development, production and distribution of genetically engineered in vitro diagnostics.
The company focuses on the serology of bacterial, viral and parasitic infections as well as on auto immune diseases.
Since 1989 Mikrogen produces antigens for clinical diagnostics. The company has an excellent expertise for the development of test systems based on recombinant antigens. The company‘s highly skilled and experienced employees are the key to the success of Mikrogen. To improve the performance of clinical diagnostics constantly, more than 120 staff members work continuously on the implementation of latest scientific results.
Mikrogen owns various patents particularly for Borrelia burgdorferi, Parvovirus B19, EBV and HCV antigens.
Mikrogen maintains worldwide research and development cooperations with various companies, scientific institutions and reference laboratories. Our customers benefit directly from Mikrogen‘s intensive scientific knowledge. Mikrogen forwards directly all latest scientific findings into the company‘s research and development, resulting in an continuous improvement of all Mikrogen tests. Mikrogen has influenced many diagnostic guidelines and is recommended by various reference laboratories.
Mikrogen‘s production process is certified according to DIN EN ISO 13485. Mikrogen‘s products are CE-marked and meet the high standards of the European directive 98/79/EC on in vitro diagnostic medical devices. The company‘s QM system guarantees the fulfillment of highest quality demands.
Mikrogen offers a wide range of test systems for the indirect detection (antibodies) and direct detection (PCR) of pathogens.
Link to Mikrogen